TAG:
biopsy
“Frankenstein the Tumor” is No More
By R. Lewis Dark | From the Volume XII No. 3 – February 14, 2005 Issue
HOW MANY OF YOU HEARD ABOUT THE TUMOR NAMED “FRANKENSTEIN”? This is a story which made national news in mid-January and again in early February. The story line is simple. A nine-year old boy in Richmond, Virginia was diagnosed in May 2003 with embryonal rhabdomyosarcoma. A grapefruit-sized tumor…
Aligning Pathologist Productivity With Compensation Can Be Challenging
By Robert Michel | From the Volume XI No. 15 – November 1, 2004 Issue
“Growing interest in ways to link a pathologist’s productivity to his/her compensation makes this a widely-discussed topic within many pathology group practices.” –Dennis Padget CEO SUMMARY: Part Three continues THE DARK REPORT’S series on meas…
Making a Difference in Tangible Ways
By R. Lewis Dark | From the Volume XI No.13 – September 20, 2004 Issue
HOW OFTEN DOES SOMETHING you learn from THE DARK REPORT make a positive difference in your laboratory? We hear lots of examples from our clients and regular readers and I’d like to share two of them with you today. The first example comes from our special, exclusive, and expanded coverage about an…
How Local Path Groups Can Keep Patient Access
By Robert Michel | From the Volume XI No.13 – September 20, 2004 Issue
CEO SUMMARY: For pathology groups operating their own histology and cytology labs, a growing problem is access to patients covered by exclusive managed care contracts. In the Northeast, several persistent pathology group practices are using some effective business strategies to fight this…
“Actionable Intelligence” In Real Time
By R. Lewis Dark | From the Volume XI No. 11 – August 9, 2004 Issue
BEFORE YOU READ THIS ISSUE, I would like to make three observations. Each will help you get maximum value from the information contained herein about the trend of in-house anatomic pathology (AP) laboratories in specialist physician groups. First, THE DARK REPORT’S coverage of this trend is unmatc…
Part II: Path Condo Labs As A Threat to Pathology
By Robert Michel | From the Volume XI No. 11 – August 9, 2004 Issue
SPECIALIST PHYSICIAN GROUPS are taking active steps to capture anatomic pathology (AP) revenues that result from specimens generated by their groups’ patients. Yet the anatomic pathology profession is only now awakening to this threat. To educate and alert pathologists and their group practice adm…
Peeking Into Finances Of Pathology Lab Condos
By Robert Michel | From the Volume XI No. 11 – August 9, 2004 Issue
CEO SUMMARY: In the possession of THE DARK REPORT is a copy of revenue and expense projections shown by a pathology condo laboratory complex promoter to prospective urology groups. They project that even smaller urology groups can realize worthwhile income if they invest in a pathology co…
AP Test Over-Utilization Will Be One Achilles’ Heel
By Robert Michel | From the Volume XI No. 11 – August 9, 2004 Issue
CEO SUMMARY: Over-utilization is likely to be a prime concern when federal healthcare enforcers eventually investigate in-house anatomic pathology laboratories owned by specialist physicians. Some in-house pathology lab condo promoters are basing financial performance on 100% utilization …
Changing Economics Motivate Urologists & GIs
By Robert Michel | From the Volume XI No. 10 – July 19, 2004 Issue
CEO SUMMARY: Over the past 18 months, more specialist groups have created their own anatomic pathology laboratories than were created in the past five years. It’s a gold rush to tap and capture profits generated by the anatomic pathology services provided to their patient populations. T…
National AP Firms Target Gastroenterology Groups
By Robert Michel | From the Volume XI No. 9 – June 28, 2004 Issue
CEO SUMMARY: It’s a trend as yet invisible to the radar screens of most pathology groups. A new crop of specialty AP companies is targeting gastroenterology. In the past 36 months, several have posted phenomenal growth in both specimen volume and revenue. The heightened competition for …
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized